tetano
Editor, Senior Moderator
ACR Open Rheumatol
. 2022 Aug 24.
doi: 10.1002/acr2.11495. Online ahead of print.
Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19: Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry
Kanon Jatuworapruk[SUP] 1 [/SUP], Anna Montgomery[SUP] 2 [/SUP], Milena Gianfrancesco[SUP] 2 [/SUP], Richard Conway[SUP] 3 [/SUP], Laura Durcan[SUP] 4 [/SUP], Elizabeth R Graef[SUP] 5 [/SUP], Aruni Jayatilleke[SUP] 6 [/SUP], Helen Keen[SUP] 7 [/SUP], Adam Kilian[SUP] 8 [/SUP], Kristen Young[SUP] 9 [/SUP], Loreto Carmona[SUP] 10 [/SUP], Adriana Karina Cogo[SUP] 11 [/SUP], Alí Duarte-García[SUP] 12 [/SUP], Laure Gossec[SUP] 13 [/SUP], Rebecca Hasseli[SUP] 14 [/SUP], Kimme L Hyrich[SUP] 15 [/SUP], Vincent Langlois[SUP] 16 [/SUP], Saskia Lawson-Tovey[SUP] 17 [/SUP], Armando Malcata[SUP] 18 [/SUP], Elsa F Mateus[SUP] 19 [/SUP], Martin Schafer[SUP] 20 [/SUP], Carlo Alberto Scirè[SUP] 21 [/SUP], Valgerdur Sigurdardottir[SUP] 22 [/SUP], Jeffrey A Sparks[SUP] 23 [/SUP], Anja Strangfeld[SUP] 20 [/SUP], Ricardo M Xavier[SUP] 24 [/SUP], Suleman Bhana[SUP] 25 [/SUP], Monique Gore-Massy[SUP] 26 [/SUP], Jonathan Hausmann[SUP] 27 [/SUP], Jean W Liew[SUP] 5 [/SUP], Emily Sirotich[SUP] 28 [/SUP], Paul Sufka[SUP] 29 [/SUP], Zach Wallace[SUP] 30 [/SUP], Pedro M Machado[SUP] 31 [/SUP], Jinoos Yazdany[SUP] 2 [/SUP], Rebecca Grainger[SUP] 32 [/SUP], Philip C Robinson[SUP] 33 [/SUP]
Affiliations
Abstract
Objective: To describe people with gout who were diagnosed with coronavirus disease 2019 (COVID-19) and hospitalized and to characterize their outcomes.
Methods: Data on patients with gout hospitalized for COVID-19 between March 12, 2020, and October 25, 2021, were extracted from the COVID-19 Global Rheumatology Alliance registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures, and COVID-19 outcomes including oxygenation or ventilation support and death.
Results: One hundred sixty-three patients with gout who developed COVID-19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre-COVID-19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID-19-related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities.
Conclusion: This cohort of people with gout and COVID-19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID-19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity.
. 2022 Aug 24.
doi: 10.1002/acr2.11495. Online ahead of print.
Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19: Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry
Kanon Jatuworapruk[SUP] 1 [/SUP], Anna Montgomery[SUP] 2 [/SUP], Milena Gianfrancesco[SUP] 2 [/SUP], Richard Conway[SUP] 3 [/SUP], Laura Durcan[SUP] 4 [/SUP], Elizabeth R Graef[SUP] 5 [/SUP], Aruni Jayatilleke[SUP] 6 [/SUP], Helen Keen[SUP] 7 [/SUP], Adam Kilian[SUP] 8 [/SUP], Kristen Young[SUP] 9 [/SUP], Loreto Carmona[SUP] 10 [/SUP], Adriana Karina Cogo[SUP] 11 [/SUP], Alí Duarte-García[SUP] 12 [/SUP], Laure Gossec[SUP] 13 [/SUP], Rebecca Hasseli[SUP] 14 [/SUP], Kimme L Hyrich[SUP] 15 [/SUP], Vincent Langlois[SUP] 16 [/SUP], Saskia Lawson-Tovey[SUP] 17 [/SUP], Armando Malcata[SUP] 18 [/SUP], Elsa F Mateus[SUP] 19 [/SUP], Martin Schafer[SUP] 20 [/SUP], Carlo Alberto Scirè[SUP] 21 [/SUP], Valgerdur Sigurdardottir[SUP] 22 [/SUP], Jeffrey A Sparks[SUP] 23 [/SUP], Anja Strangfeld[SUP] 20 [/SUP], Ricardo M Xavier[SUP] 24 [/SUP], Suleman Bhana[SUP] 25 [/SUP], Monique Gore-Massy[SUP] 26 [/SUP], Jonathan Hausmann[SUP] 27 [/SUP], Jean W Liew[SUP] 5 [/SUP], Emily Sirotich[SUP] 28 [/SUP], Paul Sufka[SUP] 29 [/SUP], Zach Wallace[SUP] 30 [/SUP], Pedro M Machado[SUP] 31 [/SUP], Jinoos Yazdany[SUP] 2 [/SUP], Rebecca Grainger[SUP] 32 [/SUP], Philip C Robinson[SUP] 33 [/SUP]
Affiliations
- PMID: 36000538
- DOI: 10.1002/acr2.11495
Abstract
Objective: To describe people with gout who were diagnosed with coronavirus disease 2019 (COVID-19) and hospitalized and to characterize their outcomes.
Methods: Data on patients with gout hospitalized for COVID-19 between March 12, 2020, and October 25, 2021, were extracted from the COVID-19 Global Rheumatology Alliance registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures, and COVID-19 outcomes including oxygenation or ventilation support and death.
Results: One hundred sixty-three patients with gout who developed COVID-19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre-COVID-19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID-19-related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities.
Conclusion: This cohort of people with gout and COVID-19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID-19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity.